KR20220140727A - 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도 - Google Patents

비알코올성 지방간염 (nash) 바이오마커 및 이의 용도 Download PDF

Info

Publication number
KR20220140727A
KR20220140727A KR1020227027222A KR20227027222A KR20220140727A KR 20220140727 A KR20220140727 A KR 20220140727A KR 1020227027222 A KR1020227027222 A KR 1020227027222A KR 20227027222 A KR20227027222 A KR 20227027222A KR 20220140727 A KR20220140727 A KR 20220140727A
Authority
KR
South Korea
Prior art keywords
subject
nash
biomarker
sample
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227027222A
Other languages
English (en)
Korean (ko)
Inventor
레이 알렉산더
라헬 오스트로프
스튜어트 필드
Original Assignee
소마로직 오퍼레이팅 컴퍼니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 filed Critical 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드
Publication of KR20220140727A publication Critical patent/KR20220140727A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227027222A 2020-02-10 2021-02-09 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도 Pending KR20220140727A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972418P 2020-02-10 2020-02-10
US62/972,418 2020-02-10
PCT/US2021/017217 WO2021163034A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
KR20220140727A true KR20220140727A (ko) 2022-10-18

Family

ID=74858782

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227027222A Pending KR20220140727A (ko) 2020-02-10 2021-02-09 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도

Country Status (12)

Country Link
US (1) US20230071234A1 (https=)
EP (1) EP4103948A1 (https=)
JP (2) JP7766605B2 (https=)
KR (1) KR20220140727A (https=)
CN (1) CN115066616A (https=)
AU (1) AU2021220787A1 (https=)
BR (1) BR112022015303A2 (https=)
CA (2) CA3300793A1 (https=)
IL (1) IL295064A (https=)
MX (1) MX2022009517A (https=)
PH (1) PH12022552003A1 (https=)
WO (1) WO2021163034A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー
WO2025090996A1 (en) * 2023-10-28 2025-05-01 Novelna Inc. Nafld detection proteins and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7824871B2 (en) * 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
JP5781436B2 (ja) * 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP3110976B1 (en) * 2014-02-27 2020-05-13 Biogen MA Inc. Method of assessing risk of pml
CA2978696A1 (en) * 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Novel methods for early identification of bone healing ability in injured patients
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
KR20180029046A (ko) * 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
US20210215711A1 (en) * 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
CN111183360B (zh) * 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合

Also Published As

Publication number Publication date
CA3166923A1 (en) 2021-08-19
JP2023512701A (ja) 2023-03-28
IL295064A (en) 2022-09-01
US20230071234A1 (en) 2023-03-09
PH12022552003A1 (en) 2024-02-05
AU2021220787A1 (en) 2022-09-01
CN115066616A (zh) 2022-09-16
BR112022015303A2 (pt) 2022-09-27
JP2026021411A (ja) 2026-02-10
WO2021163034A1 (en) 2021-08-19
EP4103948A1 (en) 2022-12-21
CA3300793A1 (en) 2026-03-02
MX2022009517A (es) 2022-09-02
JP7766605B2 (ja) 2025-11-10

Similar Documents

Publication Publication Date Title
US10359435B2 (en) Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
CN116008563B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
JP2026021411A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用
CA3161906C (en) Methods of determining impaired glucose tolerance
JP2025526256A (ja) 試料品質評価の方法
HK40078108A (en) Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40026777A (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40026777B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40090190A (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
HK1246853B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1246853A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1259917A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1220251B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902